Literature DB >> 18583630

Clinical impact of variability in HbA1c as assessed by simultaneously measuring fructosamine and use of error grid analysis.

David R Macdonald1, Alison M Hanson, Martin R Holland, Baldev M Singh.   

Abstract

BACKGROUND: Haemoglobin A1c (HbA1c) is the only measure of glycaemic control used for many patients with diabetes, but it has limitations and might sometimes be misleading. HbA(1c) concentrations are influenced by conditions that alter red-cell life and there is evidence that biochemical variation in intracellular glycation rates also influence HbA1c concentrations. This paper is the first to propose a method of using simultaneously measured HbA1c and fructosamine, and error grid analysis, in the clinical setting, to gain a better understanding of glycaemic control.
METHODS: Cross-sectional analytical study using HbA1c and fructosamine measures on the same blood sample from 1744 patients having blood taken for hospital diabetes clinic appointments. No other selection or exclusion criteria were applied.
RESULTS: The fructosamine results were converted to a HbA1c equivalent which was then compared with the HbA1c. In an Altman-Bland plot, the paired result differences ranged between -6.9% and +5.5% HbA1c with 1139 (65%), 438 (25%), 130 (8%) and 37 (2%) being < or =1%, 1-2%, 2-3% or >3% of HbA1c difference, respectively. In clinical error grid analysis, 864 (50%) results had tight concordance for clinical interpretation, 761 (43%) had one block disunity of probably little clinical significance, but 105 (6%) were two blocks and 14 (1%) were three blocks discordant.
CONCLUSION: HbA1c may not accurately reflect glucose control. Our method, utilizing co-assessment with serum fructosamine, evaluates the possible clinical impact of this. We suggest the analysis used in this paper should be used routinely in diabetes practice.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18583630     DOI: 10.1258/acb.2008.007259

Source DB:  PubMed          Journal:  Ann Clin Biochem        ISSN: 0004-5632            Impact factor:   2.057


  10 in total

1.  Clinicopathologic characteristics, prevalence, and risk factors of spontaneous diabetes in sooty mangabeys (Cercocebus atys).

Authors:  Amelia C Jones; James G Herndon; Cynthia L Courtney; Lynn Collura; Joyce K Cohen
Journal:  Comp Med       Date:  2014-06       Impact factor: 0.982

2.  Evaluation of glycemic variability in well-controlled type 2 diabetes mellitus.

Authors:  Suk Chon; Yun Jung Lee; Gemma Fraterrigo; Paolo Pozzilli; Moon Chan Choi; Mi-Kwang Kwon; Sang Ouk Chin; Sang Youl Rhee; Seungjoon Oh; Young-Seol Kim; Jeong-Taek Woo
Journal:  Diabetes Technol Ther       Date:  2013-04-25       Impact factor: 6.118

3.  Association of glycation gap with mortality and vascular complications in diabetes.

Authors:  Ananth U Nayak; Alan M Nevill; Paul Bassett; Baldev M Singh
Journal:  Diabetes Care       Date:  2013-07-08       Impact factor: 19.112

4.  Evidence for consistency of the glycation gap in diabetes.

Authors:  Ananth U Nayak; Martin R Holland; David R Macdonald; Alan Nevill; Baldev M Singh
Journal:  Diabetes Care       Date:  2011-06-29       Impact factor: 19.112

5.  Serum fructosamine a better indicator than glycated hemoglobin for monitoring gestational diabetes mellitus.

Authors:  S Ayyappan; Sachu Philips; C Kishore Kumar; V Vaithiyanandane; C Sasikala
Journal:  J Pharm Bioallied Sci       Date:  2015-04

6.  Evaluation of agreement between hemoglobin A1c, fasting glucose, and fructosamine in Senegalese individuals with and without sickle-cell trait.

Authors:  Sarah Skinner; Mor Diaw; Maïmouna Ndour Mbaye; Philippe Joly; Céline Renoux; Céline Masson; Charlotte Cuerq; Philomène Lopez; Malick Ndour; Demba Diedhiou; Djiby Sow; Saliou Diop; Abdoulaye Samb; Vincent Pialoux; Philippe Connes
Journal:  PLoS One       Date:  2019-02-15       Impact factor: 3.240

7.  Serum fructosamine and glycemic status in the presence of the sickle cell mutation.

Authors:  Ayo P Doumatey; Hermon Feron; Kenneth Ekoru; Jie Zhou; Adebowale Adeyemo; Charles N Rotimi
Journal:  Diabetes Res Clin Pract       Date:  2021-06-11       Impact factor: 8.180

Review 8.  Importance of Glycemic Control in Cancer Patients with Diabetes: Treatment through End of Life.

Authors:  Denise Soltow Hershey
Journal:  Asia Pac J Oncol Nurs       Date:  2017 Oct-Dec

9.  Role of fructosamine-3-kinase in protecting against the onset of microvascular and macrovascular complications in patients with T2DM.

Authors:  Giovanni Sartore; Eugenio Ragazzi; Silvia Burlina; Renata Paleari; Nino Cristiano Chilelli; Andrea Mosca; Francesca Avemaria; Annunziata Lapolla
Journal:  BMJ Open Diabetes Res Care       Date:  2020-05

10.  Increased body fat mass reduces the association between fructosamine and glycated hemoglobin in obese type 2 diabetes patients.

Authors:  Bruno Vergès; Alexia Rouland; Sabine Baillot-Rudoni; Marie-Claude Brindisi; Laurence Duvillard; Isabelle Simoneau; Pauline Legris; Jean-Michel Petit; Benjamin Bouillet
Journal:  J Diabetes Investig       Date:  2020-09-17       Impact factor: 4.232

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.